
Fragment-based Drug Discovery
Description
Global Fragment-based Drug Discovery Market to Reach US$1.6 Billion by 2030
The global market for Fragment-based Drug Discovery estimated at US$977.0 Million in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Fragment Optimization segment is estimated at 7.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$270.8 Million While China is Forecast to Grow at 8.2% CAGR
The Fragment-based Drug Discovery market in the U.S. is estimated at US$270.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$248.7 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.
Global Fragment-Based Drug Discovery Market - Key Trends & Drivers Summarized
Why Is Fragment-Based Drug Discovery a Game Changer in Pharmaceuticals?
Fragment-Based Drug Discovery (FBDD) has revolutionized pharmaceutical research by allowing scientists to develop drugs with higher specificity and efficacy. Unlike traditional drug discovery, FBDD involves screening smaller, “fragment” molecules that bind to target sites on proteins, which can then be optimized into potent drugs. This approach is particularly effective for complex disease targets such as cancer, where traditional methods have struggled. FBDD accelerates the drug discovery process and often leads to more viable drug candidates, making it a valuable approach for addressing unmet medical needs.
How Are Advanced Screening Techniques Enhancing FBDD?
The success of FBDD heavily relies on advanced screening technologies that enable the identification of fragment interactions with target proteins. Techniques like nuclear magnetic resonance (NMR), X-ray crystallography, and high-throughput screening allow researchers to visualize binding interactions in detail, facilitating more precise drug design. Recent advancements in AI-driven screening and computational modeling further optimize the FBDD process by predicting fragment-target binding more accurately. These innovations make FBDD a faster, more efficient, and cost-effective approach to drug discovery, appealing to pharmaceutical companies aiming for shorter development timelines.
What Role Does FBDD Play in Cancer and Neurological Research?
FBDD is particularly valuable in oncology and neurological research, where complex and traditionally “undruggable” targets are common. Cancer research, for example, benefits from FBDD’s ability to identify small molecule inhibitors that can precisely target and disrupt cancer cell growth mechanisms. Similarly, in neurological disorders, FBDD aids in discovering treatments that can cross the blood-brain barrier, addressing diseases like Alzheimer’s and Parkinson’s. The ability of FBDD to uncover novel therapeutic options for difficult-to-treat conditions makes it a growing area of focus in medical research.
What Drives Growth in the Fragment-Based Drug Discovery Market?
The growth in the FBDD market is driven by advancements in screening technologies, rising demand for targeted therapies, and its applications in challenging disease areas. New screening tools and AI-driven computational models enhance the efficiency of FBDD, attracting pharmaceutical companies looking for cost-effective drug discovery methods. The demand for targeted therapies, especially in oncology and neurology, further fuels FBDD adoption. Moreover, FBDD’s ability to identify novel treatment options for complex diseases provides a pathway for addressing unmet medical needs, making it a crucial area in modern pharmaceutical research.
SCOPE OF STUDY:The report analyzes the Fragment-based Drug Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Technology (Fragment Screening, Fragment Optimization); End-Use (Biopharmaceutical Companies, Academic & Research Institutions, Contract Research Organizations)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 44 Featured) -
- Akaal Pharma Pty. Ltd.
- Algorae Pharmaceuticals Ltd.
- Aragen Life Sciences Ltd.
- Beactica Therapeutics AB
- Carna Biosciences, Inc.
- Charles River Laboratories International, Inc.
- Crelux
- Evotec SE
- Marsala Biotech Inc.
- PsychoGenics, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Tariff Impact on Global Supply Chain Patterns
- Fragment-based Drug Discovery – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Demand for Faster and Cost-Effective Drug Discovery Methods
- Increased Focus on Precision Medicine and Targeted Therapy Development
- Technological Advancements in High-Throughput Screening and X-Ray Crystallography
- Growth in Collaboration Between Pharmaceutical Companies and Academic Institutions
- Expansion of Fragment-Based Drug Discovery for Oncology and CNS Disorders
- Growing Adoption of Fragment-Based Approaches in Drug Design for Complex Diseases
- Surge in Demand for Fragment Libraries with High Chemical Diversity
- Increased Investment in Artificial Intelligence for Accelerating Drug Discovery
- Expansion of Fragment-Based Drug Discovery in Rare and Orphan Diseases
- Rising Use of Fragment-Based Techniques to Reduce Drug Toxicity and Side Effects
- Growth in Biopharma R&D Spending on Novel Therapeutics Using Fragment-Based Methods
- Demand for Software Tools and Platforms to Enhance Fragment-Based Research
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Fragment-based Drug Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Fragment-based Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Fragment Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Fragment Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Fragment Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Fragment Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Fragment Optimization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Fragment Optimization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Academic & Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Academic & Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 20: USA Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 21: USA Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 22: USA 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 23: USA Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 24: USA Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 25: USA 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- CANADA
- TABLE 26: Canada Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 27: Canada Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 28: Canada 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 29: Canada Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 31: Canada 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- JAPAN
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 32: Japan Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 34: Japan 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 35: Japan Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 36: Japan Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 37: Japan 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- CHINA
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 38: China Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 39: China Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 40: China 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 41: China Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 42: China Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 43: China 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- EUROPE
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 44: Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
- TABLE 45: Europe Historic Review for Fragment-based Drug Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 46: Europe 15-Year Perspective for Fragment-based Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 47: Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 48: Europe Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 49: Europe 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 50: Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 51: Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 52: Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- FRANCE
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 53: France Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 54: France Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 55: France 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 56: France Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 57: France Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 58: France 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- GERMANY
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 59: Germany Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 60: Germany Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 61: Germany 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 62: Germany Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 63: Germany Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 64: Germany 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- ITALY
- TABLE 65: Italy Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 66: Italy Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 67: Italy 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 68: Italy Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 69: Italy Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 70: Italy 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 71: UK Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 72: UK Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 73: UK 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 74: UK Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 75: UK Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 76: UK 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 78: Rest of Europe Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 79: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 81: Rest of Europe Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 82: Rest of Europe 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Fragment-based Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 84: Asia-Pacific Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 85: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 87: Asia-Pacific Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 88: Asia-Pacific 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- REST OF WORLD
- TABLE 89: Rest of World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of World Historic Review for Fragment-based Drug Discovery by Technology - Fragment Screening and Fragment Optimization Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 91: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by Technology - Percentage Breakdown of Value Sales for Fragment Screening and Fragment Optimization for the Years 2015, 2025 & 2030
- TABLE 92: Rest of World Recent Past, Current & Future Analysis for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
- TABLE 93: Rest of World Historic Review for Fragment-based Drug Discovery by End-Use - Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
- TABLE 94: Rest of World 15-Year Perspective for Fragment-based Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Academic & Research Institutions and Contract Research Organizations for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates